PCOS Is Now PMOS: Why the Renaming Reshapes Women's Care

Global health experts have officially renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome following an extensive international consensus process. Consequently, this critical shift reframes a complex lifelong disorder that clinicians frequently misunderstood. The legacy name perpetuated the inaccurate belief that the condition represents an isolated ovarian defect with true ovarian cysts. Instead, the ovarian morphology reflects multiple arrested antral follicles alongside systemic endocrine dysregulation. Moreover, the updated nomenclature captures the multisystem reality of this condition across a woman's lifespan.

Why Polyendocrine Metabolic Ovarian Syndrome Corrects a Misnomer

For decades, the historical term focused almost exclusively on reproductive concerns and ovarian anatomy. However, true cysts do not form in this condition. Rather, ultrasound scans identify arrested antral follicles that fail to mature because of complex hormonal feedback loops. Therefore, the old terminology created substantial confusion for both patients and clinicians. In addition, women frequently delayed necessary metabolic evaluations because they assumed their ovaries were the sole problem. By embedding both endocrine and metabolic dimensions into the diagnostic title, the new name establishes a modern foundation for multidisciplinary medical management.

Diagnostic Criteria and Clinical Recognition

Importantly, the core diagnostic criteria remain identical despite the nomenclature transition. Clinicians continue to confirm the diagnosis when a patient meets at least two of three established criteria. First, physicians assess ovulatory dysfunction manifesting as irregular menstrual cycles or oligo-anovulation. Second, providers identify clinical or biochemical hyperandrogenism. Third, practitioners verify elevated anti-Müllerian hormone concentrations or characteristic follicular patterns on pelvic ultrasound. Consequently, clinicians do not need to alter their routine diagnostic testing protocols. Nevertheless, obstetricians and gynecologists must expand their therapeutic focus beyond menstrual regularity and fertility optimization.

Antenatal Risks and Obstetric Management

The condition significantly alters maternal and perinatal risk profiles during pregnancy. For example, affected women experience higher rates of gestational diabetes, preeclampsia, and preterm delivery. Furthermore, pregnancies carry increased hazards of fetal growth restriction, low birthweight, and cesarean delivery. Notably, these associations persist even after researchers adjust for maternal age and body mass index. Obstetric teams rarely document this disorder as a key risk modifier during early booking visits. Thus, prenatal care plans frequently miss opportunities for early glucose monitoring and blood pressure surveillance. Gynecologists must therefore integrate targeted metabolic tracking into routine antenatal workflows.

Lifelong Cardiometabolic and Psychological Care

Beyond reproductive years, the syndrome drives substantial systemic morbidity. In particular, insulin resistance accelerates the progression toward impaired glucose tolerance and type 2 diabetes. Similarly, patients face elevated rates of dyslipidemia, hepatic steatosis, and hypertension across life. Additionally, clinicians frequently overlook associated anxiety, depressive disorders, and impaired quality of life. Therefore, practitioners should screen all patients for cardiometabolic markers and emotional health challenges regularly. Proactive lifestyle modifications, combined with timely medical therapy, substantially mitigate long-term cardiovascular harm.

Frequently Asked Questions

Q1: Why did global experts change the name of polycystic ovary syndrome?

International consensus committees changed the name because the legacy title was medically inaccurate. Specifically, the ovaries contain arrested antral follicles rather than pathological cysts, and the syndrome involves widespread endocrine and metabolic dysfunction.

Q2: Did the diagnostic criteria change alongside the new name?

No, the core diagnostic criteria remain unchanged. Clinicians still require at least two of three features: ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology or elevated anti-Müllerian hormone levels.

Q3: How does this condition affect pregnancy outcomes?

Women face significantly higher risks of gestational diabetes, hypertensive disorders, preterm delivery, and fetal growth restriction. Consequently, obstetricians must implement early antenatal screening and proactive metabolic monitoring.

For healthcare professionals seeking to deepen their expertise, exploring specialized womens health courses can greatly enhance patient care outcomes.

References

1. Bahri-Khomami M et al. From polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome: what obstetricians and gynecologists need to know. Am J Obstet Gynecol. 2026 Sep 10. doi: undefined. PMID: 42665241.
2. Teede HJ, Bahri Khomami M, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339.
3. Teede HJ, Tay CT, Laven JSE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43-G64.